NEW YORK, Jan. 8, 2012 /PRNewswire/ -- The Law Office
of James C. Kelly announces that it
is investigating potential claims against the board of directors of
Inhibitex, Inc. ("Inhibitex" or the "Company") (NasdaqCM: INHX)
concerning possible breaches of fiduciary duty and other violations
of law related to the Company's entry into an agreement to be
acquired by Bristol-Myers Squibb Company ("Bristol-Myers") in a
transaction with an approximate value of $2.5 billion.
Under the proposed agreement, Bristol-Myers will commence a
tender offer to acquire all of the outstanding shares of
Inhibitex's common stock at a price of $26.00 per share in cash.
The investigation concerns whether Inhibitex's board of
directors adequately shopped the Company to obtain the best price
possible for the Company's shareholders before entering into the
agreement with Bristol-Myers.
If you are a holder of Inhibitex common stock and want to
discuss your legal rights, you may e-mail or call The Law Office of
James C. Kelly who will, without
obligation or cost to you, attempt to answer your questions.
Please contact James C. Kelly, Esq.,
of The Law Office of James C. Kelly,
477 Madison Avenue, New York, New
York 10022, by toll free telephone at (888) 643-7517 or by
sending an e-mail including your contact information to:
jkelly@jckellylaw.com.
The Law Office of James C. Kelly
is a New York City-based law firm
with significant experience representing investors in
merger-related shareholder class actions, shareholder derivative
actions, and securities fraud class actions. For more information
about the firm, please visit its website at
http://www.jckellylaw.com.
Attorney advertising. Prior results do not guarantee a similar
outcome.
SOURCE The Law Office of James C.
Kelly
